Misplaced Pages

Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.

A phase I/II trial in patients with malignant ascites was terminated in 2016.

References

1. Douillard P, Thiele M, Schinagl A, Halama N, Jaeger D, Yazji S, Scheiflinger F, Kerschbaumer R (2015). "Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (OxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients". Therapeutic Agents: Biological. Vol. 14. pp. A153. doi:10.1158/1535-7163.TARG-15-A153. {{cite book}}: |journal= ignored (help)
2. ^ Clinical trial number NCT02448810 for "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer" at ClinicalTrials.gov
3. Clinical trial number NCT01765790 for "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumor" at ClinicalTrials.gov
4. ^ "Imalumab". AdisInsight. Springer Nature Switzerland AG.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Monoclonal antibodies for tumors
• Experimental cancer drugs
• Monoclonal antibody stubs